Natera, Inc. (NTRA)
NTRA Stock Price Chart
Explore Natera, Inc. interactive price chart. Choose custom timeframes to analyze NTRA price movements and trends.
NTRA Company Profile
Discover essential business fundamentals and corporate details for Natera, Inc. (NTRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
1 Jul 2015
Employees
4.42K
Website
https://www.natera.comCEO
Steven Leonard Chapman
Description
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
NTRA Financial Timeline
Browse a chronological timeline of Natera, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.40.
Earnings released on 7 Aug 2025
EPS came in at -$0.74 falling short of the estimated -$0.60 by -23.33%, while revenue for the quarter reached $546.60M , beating expectations by +6.19%.
Earnings released on 8 May 2025
EPS came in at -$0.50 surpassing the estimated -$0.64 by +21.93%, while revenue for the quarter reached $501.83M , beating expectations by +12.46%.
Earnings released on 27 Feb 2025
EPS came in at -$0.41 falling short of the estimated -$0.38 by -7.57%, while revenue for the quarter reached $476.06M , beating expectations by +9.28%.
Earnings released on 12 Nov 2024
EPS came in at -$0.26 surpassing the estimated -$0.57 by +54.75%, while revenue for the quarter reached $439.76M , beating expectations by +21.67%.
Earnings released on 8 Aug 2024
EPS came in at -$0.30 surpassing the estimated -$0.69 by +56.44%, while revenue for the quarter reached $413.35M , beating expectations by +20.51%.
Earnings released on 9 May 2024
EPS came in at -$0.56 surpassing the estimated -$0.71 by +20.59%, while revenue for the quarter reached $367.74M , beating expectations by +16.26%.
Earnings released on 28 Feb 2024
EPS came in at -$0.64 surpassing the estimated -$0.73 by +12.33%, while revenue for the quarter reached $311.11M , beating expectations by +3.70%.
Earnings released on 8 Nov 2023
EPS came in at -$0.95 surpassing the estimated -$0.96 by +1.04%, while revenue for the quarter reached $268.31M , beating expectations by +3.53%.
Earnings released on 3 Aug 2023
EPS came in at -$0.97 surpassing the estimated -$1.09 by +11.01%, while revenue for the quarter reached $261.40M , beating expectations by +2.21%.
Earnings released on 9 May 2023
EPS came in at -$1.23 falling short of the estimated -$1.18 by -4.24%, while revenue for the quarter reached $241.76M , beating expectations by +6.19%.
Earnings released on 28 Feb 2023
EPS came in at -$1.37 surpassing the estimated -$1.40 by +2.14%, while revenue for the quarter reached $217.25M , beating expectations by +0.78%.
Earnings released on 8 Nov 2022
EPS came in at -$1.25 surpassing the estimated -$1.42 by +11.97%, while revenue for the quarter reached $210.64M , beating expectations by +1.93%.
Earnings released on 4 Aug 2022
EPS came in at -$1.50 falling short of the estimated -$1.47 by -2.04%, while revenue for the quarter reached $198.20M , beating expectations by +2.34%.
Earnings released on 5 May 2022
EPS came in at -$1.45 surpassing the estimated -$1.50 by +3.33%, while revenue for the quarter reached $194.13M , missing expectations by -1.99%.
Earnings released on 24 Feb 2022
EPS came in at -$1.48 falling short of the estimated -$1.24 by -19.35%, while revenue for the quarter reached $173.03M , beating expectations by +2.42%.
Earnings released on 4 Nov 2021
EPS came in at -$1.63 falling short of the estimated -$1.27 by -28.35%, while revenue for the quarter reached $158.12M , beating expectations by +4.84%.
Earnings released on 5 Aug 2021
EPS came in at -$1.32 falling short of the estimated -$1.05 by -25.71%, while revenue for the quarter reached $142.03M , beating expectations by +9.50%.
Earnings released on 6 May 2021
EPS came in at -$0.74 surpassing the estimated -$1.05 by +29.52%, while revenue for the quarter reached $152.32M , missing expectations by -21.54%.
Earnings released on 25 Feb 2021
EPS came in at -$0.89 falling short of the estimated -$0.61 by -45.90%, while revenue for the quarter reached $112.38M , beating expectations by +17.42%.
Earnings released on 5 Nov 2020
EPS came in at -$0.72 falling short of the estimated -$0.67 by -7.46%, while revenue for the quarter reached $98.14M , beating expectations by +5.88%.
NTRA Stock Performance
Access detailed NTRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.